CORRECTION - Sorrento Therapeutics, Inc.
Sorrento Therapeutics (NASDAQ: SRNE) announced Dr. Henry Ji's participation in the Benzinga Healthcare Small Cap Conference on September 29th. He will provide company updates at 11:30 AM ET and participate in a panel discussion at 12:35 PM EDT. The conference aims to gather small-cap healthcare companies and includes live presentations. Interested parties can register for free to attend the event. Sorrento is known for its development of therapies for cancer, pain, autoimmune diseases, and COVID-19, utilizing various innovative technologies.
- Participation in the Benzinga Healthcare Small Cap Conference may enhance visibility for Sorrento Therapeutics.
- Dr. Ji's presentation may provide valuable insights and updates on Sorrento's initiatives and product developments.
- None.
SAN DIEGO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- In a release issued on Tuesday, September 28th by Sorrento Therapeutics, Inc. (NASDAQ: SRNE), please note that the date of the conference has been corrected to "September 29th" in the headline. The corrected release follows:
Sorrento to Participate in the Benzinga Healthcare Small Cap Conference on September 29th
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") is pleased to announce that Dr. Henry Ji, Chairman and CEO, will be participating in the Benzinga Healthcare Small Cap Conference.
Dr. Ji will be providing company updates at 11:30 AM ET as well as participating in a panel discussion at 12:35 PM EDT.
The link below will allow participants to watch the presentation and panel live. Free registration is required for the event.
https://www.benzinga.com/events/small-cap/healthcare/september-29-track-1/
(Note: Link will expire 90 days after the date of recording).
For more information visit www.sorrentotherapeutics.com
About Sorrento Therapeutics, Inc.
Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates (“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVIGUARD™, COVI-AMG™, COVISHIELD™, COVI-MSC™ and COVIDROPS™; and diagnostic test solutions, including COVITRACK™, COVISTIX™ and COVITRACE™.
Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system)
For more information visit www.sorrentotherapeutics.com.
Forward-Looking Statements
This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc. and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the expectations for Sorrento's and its subsidiaries' technologies and product candidates. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's and its subsidiaries' technologies and prospects; risks related to seeking regulatory approvals and conducting clinical trials; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2020, as amended, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release except as required by law.
Media and Investor Relations Contact
Alexis Nahama, DVM (SVP Corporate Development)
Email: mediarelations@sorrentotherapeutics.com
Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.
G-MAB™, DAR-T™, SOFUSA™, MuVAXX™, COVIGUARD™, COVI-AMG™, COVISHIELD™, COVIDROPS™, COVI-MSC™, COVITRACK™, COVITRACE™ and COVISTIX™ are trademarks of Sorrento Therapeutics, Inc.
SEMDEXA™ is a trademark of Semnur Pharmaceuticals, Inc.
ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc.
All other trademarks are the property of their respective owners.
©2021 Sorrento Therapeutics, Inc. All Rights Reserved.
FAQ
What is the date of Sorrento Therapeutics' conference participation?
Who will represent Sorrento Therapeutics at the Benzinga Healthcare Conference?
What time will Dr. Ji present at the Benzinga Healthcare Conference?
Is there a registration fee to attend the Benzinga Healthcare Small Cap Conference?
